$APTOF

Seizinger Bernd R. sold (to issuer) $29K of APTOF

Seizinger Bernd R. sold (to issuer) 17,000 shares of Aptose Biosciences Inc. (APTOF) at $1.72 on 2026-06-30.

Original reporting
SEC EDGAR · Seizinger Bernd R.
Published Jul 2, 2026, 3:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 3:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$APTOF
Neutral
medium confidence
Mentioned
$APTOF
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APTOFNeutralLow
01

Why it matters

The filing updates insider ownership (ending at 0 shares) but does not introduce new operational, clinical, or financial guidance.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosed transaction size and lack of new fundamentals suggest limited immediate repricing impact.

03

What to watch

No 10b5-1 plan is indicated, but the filing also provides no reason for the sale; without follow-on buys/sells, the signal is weak.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-02 after-hours/late session; reflects 2026-06-30 transaction.

Background

This is an SEC Form 4 insider transaction disclosure for Aptose Biosciences Inc.

Company-level read

Ticker impact

$APTOFNeutralMedium confidence
Context

Aptose Biosciences insider Seizinger Bernd R. sold 17,000 shares to the issuer at $1.72 on 2026-06-30, leaving 0 shares.

Expected impact

Low near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 is primary-source, but the transaction is modest ($29.2k) and described as sale to issuer with no stated new company catalyst.

Market effects

None—single-company Form 4 with small dollar value.

None.

None.

Counterpoint

Because it’s a sale to the issuer (often tied to structured programs like buyback participation), it may reflect liquidity/plan mechanics rather than bearish conviction.

Key entities

  • Aptose Biosciences Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Seizinger Bernd R.

    Reported insider who sold 17,000 shares to the issuer at $1.72.

Related articles

$APTOFMed

Aptose Biosciences Inc. (APTOF): Completion of Acquisition or Disposition of Assets

Aptose Biosciences Inc. (APTOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0000882361 0000882361 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30,